risperidone has been researched along with Diabetes Mellitus, Type 2 in 40 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Comparisons of diabetic potential, glucose related metabolic levels, and insulin resistance between olanzapine and risperidone have produced variable results in cross-sectional and epidemiologic studies." | 9.14 | Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 7.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "Olanzapine and risperidone may impair glucose tolerance due in part to increased insulin resistance." | 7.75 | Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009) |
| "To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes)." | 5.33 | Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. ( Cunningham, FE; Dalack, GW; Hur, K; Lambert, BL; Miller, DR, 2006) |
| "Comparisons of diabetic potential, glucose related metabolic levels, and insulin resistance between olanzapine and risperidone have produced variable results in cross-sectional and epidemiologic studies." | 5.14 | Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009) |
| "Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms." | 3.85 | Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. ( Hongkaew, Y; Intachak, B; Kroll, MH; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanavanan, S; Vanwong, N, 2017) |
| " Throughout the whole clinical course mentioned above, he was under treatment for schizophrenia with drugs including risperidone which possibly affects glucose metabolism." | 3.76 | The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. ( Tsutsumi, E; Yamaguchi, K, 2010) |
| "Olanzapine and risperidone may impair glucose tolerance due in part to increased insulin resistance." | 3.75 | Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. ( Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Sato, Y; Yasui-Furukori, N, 2009) |
| "Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects." | 3.73 | Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. ( Allison, DB; Anderson, EJ; Borba, CP; Cagliero, E; Copeland, PM; Daley, TB; Evins, AE; Goff, DC; Hayden, D; Henderson, DC; Schoenfeld, D; Weber, MT, 2005) |
| "To examine the risk of developing type 2 diabetes mellitus among people with schizophrenia exposed to atypical antipsychotics (clozapine, olanzapine, quetiapine, risperidone) compared to those exposed to conventional antipsychotics." | 3.73 | Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. ( Carson, W; Chang, KY; Chou, CH; Lambert, BL; Tafesse, E, 2005) |
| " To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| "Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics." | 2.42 | The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. ( Citrome, L; Volavka, J, 2004) |
| "Incident type 2 diabetes mellitus identified through visit and pharmacy claims during the observation period." | 1.42 | Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. ( Feudtner, C; Huang, YS; Kreider, AR; Localio, AR; Matone, M; Ross, ME; Rubin, DM, 2015) |
| "Type 2 diabetes is a major health problem in individuals with schizophrenia." | 1.35 | Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. ( Dickerson, F; Leister, F; Origoni, A; Rubalcaba, E; Stallings, C; Sullens, A; Viscidi, R; Yang, S; Yolken, R, 2008) |
| "Insulin resistance is the result of the multiple effects of the antipsychotics, among which most common are: increased body mass and direct involvement of the antipsychotics in the glucose metabolism." | 1.34 | Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone. ( Degmecić, D; Filaković, P; Koić, O; Laufer, D; Pozgain, I; Radanović-Grgurić, L, 2007) |
| "To evaluate risk of new-onset type 2 diabetes associated with use of selected antipsychotic agents, the authors conducted a new-user cohort study in a national sample of US Veterans Health Administration patients with schizophrenia (and no preexisting diabetes)." | 1.33 | Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. ( Cunningham, FE; Dalack, GW; Hur, K; Lambert, BL; Miller, DR, 2006) |
| "The odds of newly reported type 2 diabetes in patients who received risperidone were not significantly different from those in untreated patients (12-month odds ratio [OR] = 1." | 1.32 | Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. ( Gianfrancesco, F; Grogg, A; Mahmoud, R; Meletiche, D; Wang, RH, 2003) |
| " Clinicians should attempt to treat patients with the lowest effective dosage of medication for the briefest therapeutic period to minimize the risks of adverse reactions." | 1.31 | Metoclopramide-induced supersensitivity psychosis. ( Lu, ML; Pan, JJ; Shen, WW; Su, KP; Teng, HW, 2002) |
| "Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded." | 1.31 | Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (72.50) | 29.6817 |
| 2010's | 11 (27.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okumura, Y | 1 |
| Usami, M | 1 |
| Okada, T | 1 |
| Saito, T | 1 |
| Negoro, H | 1 |
| Tsujii, N | 1 |
| Fujita, J | 1 |
| Iida, J | 1 |
| Moisan, J | 1 |
| Turgeon, M | 1 |
| Desjardins, O | 1 |
| Grégoire, JP | 1 |
| Vale, TC | 1 |
| Freitas, Dda S | 1 |
| Maciel, RO | 1 |
| Miranda, EC | 1 |
| Cardoso, F | 1 |
| Rubin, DM | 1 |
| Kreider, AR | 1 |
| Matone, M | 1 |
| Huang, YS | 1 |
| Feudtner, C | 1 |
| Ross, ME | 1 |
| Localio, AR | 1 |
| Srisawasdi, P | 1 |
| Vanwong, N | 1 |
| Hongkaew, Y | 1 |
| Puangpetch, A | 1 |
| Vanavanan, S | 1 |
| Intachak, B | 1 |
| Ngamsamut, N | 1 |
| Limsila, P | 1 |
| Sukasem, C | 1 |
| Kroll, MH | 1 |
| Dickerson, F | 1 |
| Rubalcaba, E | 1 |
| Viscidi, R | 1 |
| Yang, S | 1 |
| Stallings, C | 1 |
| Sullens, A | 1 |
| Origoni, A | 1 |
| Leister, F | 1 |
| Yolken, R | 1 |
| Yasui-Furukori, N | 1 |
| Sato, Y | 1 |
| Furukori, H | 1 |
| Saito, M | 1 |
| Nakagami, T | 1 |
| Kaneko, S | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 1 |
| de Leon, J | 1 |
| Blakemore, AF | 1 |
| Arranz, MJ | 1 |
| Khan, RA | 1 |
| Mican, LM | 1 |
| Suehs, BT | 1 |
| Smith, RC | 1 |
| Lindenmayer, JP | 1 |
| Davis, JM | 1 |
| Kelly, E | 1 |
| Viviano, TF | 1 |
| Cornwell, J | 1 |
| Hu, Q | 1 |
| Khan, A | 1 |
| Vaidhyanathaswamy, S | 1 |
| Park, S | 2 |
| Sapunar Z, J | 1 |
| Muñoz N, S | 1 |
| Vásquez A, T | 1 |
| Hong, SM | 1 |
| Ahn, IL | 1 |
| Kim, DS | 1 |
| Kim, SH | 1 |
| Yamaguchi, K | 1 |
| Tsutsumi, E | 1 |
| Guo, Z | 1 |
| L'italien, GJ | 1 |
| Jing, Y | 1 |
| Baker, RA | 1 |
| Forbes, RA | 1 |
| Hebden, T | 1 |
| Kim, E | 1 |
| Manu, P | 1 |
| Correll, CU | 1 |
| Wampers, M | 1 |
| van Winkel, R | 1 |
| Yu, W | 1 |
| Shiffeldrim, D | 1 |
| Kane, JM | 1 |
| De Hert, M | 1 |
| Strassnig, M | 1 |
| Awerbuck, J | 1 |
| Ganguli, R | 1 |
| Lu, ML | 1 |
| Pan, JJ | 1 |
| Teng, HW | 1 |
| Su, KP | 2 |
| Shen, WW | 1 |
| Wirshing, DA | 1 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Marder, SR | 1 |
| Wirshing, WC | 1 |
| Gianfrancesco, FD | 1 |
| Grogg, AL | 1 |
| Mahmoud, RA | 1 |
| Wang, RH | 2 |
| Nasrallah, HA | 1 |
| Gianfrancesco, F | 1 |
| Grogg, A | 1 |
| Mahmoud, R | 1 |
| Meletiche, D | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Compton, MT | 1 |
| Hill, HA | 1 |
| Citrome, L | 1 |
| Volavka, J | 1 |
| Henderson, DC | 1 |
| Cagliero, E | 1 |
| Copeland, PM | 1 |
| Borba, CP | 1 |
| Evins, AE | 1 |
| Hayden, D | 1 |
| Weber, MT | 1 |
| Anderson, EJ | 1 |
| Allison, DB | 1 |
| Daley, TB | 1 |
| Schoenfeld, D | 1 |
| Goff, DC | 1 |
| Lambert, BL | 2 |
| Chou, CH | 1 |
| Chang, KY | 1 |
| Tafesse, E | 1 |
| Carson, W | 1 |
| Filaković, P | 2 |
| Laufer, D | 2 |
| Radanović-Grgurić, L | 2 |
| Koić, O | 2 |
| Fijacko, M | 1 |
| Durković, M | 1 |
| Wu, PL | 1 |
| Lane, HY | 1 |
| Dibben, CR | 1 |
| Kalavalapalli, SS | 1 |
| Linnington, HE | 1 |
| Hynes, FA | 1 |
| Dinneen, SF | 1 |
| Adler, AI | 1 |
| McKenna, PJ | 1 |
| Lin, EJ | 1 |
| Lee, NJ | 1 |
| Slack, K | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Herzog, H | 1 |
| Sainsbury, A | 1 |
| Cunningham, FE | 1 |
| Miller, DR | 1 |
| Dalack, GW | 1 |
| Hur, K | 1 |
| Bellack, AS | 1 |
| Brown, CH | 1 |
| Thomas-Lohrman, S | 1 |
| Agius, M | 1 |
| Murphy, CL | 1 |
| Win, A | 1 |
| Zaman, R | 1 |
| Cohen, D | 1 |
| Perlis, RH | 1 |
| Perez-Iglesias, R | 1 |
| Crespo-Facorro, B | 1 |
| Amado, JA | 1 |
| Garcia-Unzueta, MT | 1 |
| Ramirez-Bonilla, ML | 1 |
| Gonzalez-Blanch, C | 1 |
| Martinez-Garcia, O | 1 |
| Vazquez-Barquero, JL | 1 |
| Degmecić, D | 1 |
| Pozgain, I | 1 |
| Sernyak, MJ | 1 |
| Leslie, DL | 1 |
| Alarcon, RD | 1 |
| Losonczy, MF | 1 |
| Rosenheck, R | 1 |
| Mallya, A | 1 |
| Chawla, P | 1 |
| Boyer, SK | 1 |
| DeRosear, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism[NCT00287820] | Phase 4 | 46 participants (Anticipated) | Interventional | 2004-02-29 | Completed | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
4 reviews available for risperidone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[Risk of type 2 diabetes mellitus among users of atypical antipsychotic drugs or conventional treatment: systematic review and meta-analysis].
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Diabetes Mellitus, Type 2; Humans; Mental Disorder | 2009 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzoth | 2004 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete | 2007 |
3 trials available for risperidone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Chronic Disease; | 2009 |
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gluc | 2005 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
33 other studies available for risperidone and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Diabetes Mellitus, Type 2; Female; Glucose; H | 2018 |
Comparative safety of antipsychotics: another look at the risk of diabetes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapine; Cohort Studies; Diabe | 2013 |
Teaching Video NeuroImages: hemichorea-hemiballismus secondary to nonketotic hyperglycemia.
Topics: Antipsychotic Agents; Brain; Chorea; Diabetes Mellitus, Type 2; Dyskinesias; Female; Humans; Hypergl | 2013 |
Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Child; Diabetes Mellitus, Type 2; Drug Syne | 2015 |
Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders.
Topics: Adiponectin; Adolescent; Antipsychotic Agents; Autistic Disorder; Blood Glucose; C-Reactive Protein; | 2017 |
Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.
Topics: 3' Untranslated Regions; Antigens, CD; Antipsychotic Agents; Benzodiazepines; CD48 Antigen; Chromoso | 2008 |
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gluc | 2009 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Diabetes Mellitus, Type 2 | 2009 |
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Cell Separation; | 2010 |
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Eating; E | 2010 |
The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antipsychotic Agents; Benzimidazol | 2010 |
A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Diabetes Mellitus, Type 2; Dibenzo | 2011 |
Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
Topics: Adult; Antipsychotic Agents; Area Under Curve; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2 | 2013 |
Diabetes resolution following discontinuation of a second-generation antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Female; Follow-U | 2013 |
Metoclopramide-induced supersensitivity psychosis.
Topics: Aged; Antiemetics; Antipsychotic Agents; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Hallucina | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte | 2002 |
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Data Collection; Diabetes Mellitus, Type 2; Female; Hu | 2003 |
Potential for detection bias in the association between olanzapine and diabetes.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; H | 2004 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Clozapine | 2005 |
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cali | 2005 |
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Disease Progression; Humans | 2006 |
Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Humans; Hypoglyc | 2005 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type | 2006 |
Psychometric characteristics of role-play assessments of social skill in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Comorbidity; Crime Victims; Diabetes Mellitus, Type 2; Femal | 2006 |
Atypical antipsychotic prescribing and diabetes.
Topics: Antipsychotic Agents; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Risperidone; Schi | 2007 |
Effect of risperidone on ghrelin and glucose in schizophrenia.
Topics: Antipsychotic Agents; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Ghrelin; Hu | 2007 |
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Diabetes Mellitus, Type 2; Female; Gl | 2007 |
[Schizophrenia and diabetes alliance. No increased insulin resistance due to risperidone].
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Risperidone; Schiz | 2001 |
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Clozapi | 2002 |
Resolution of hyperglycemia on risperidone discontinuation: a case report.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia | 2002 |